Emilia Montagna1, Sara Pirola2, Patrick Maisonneuve3, Giuseppe De Roberto4, Giuseppe Cancello5, Antonella Palazzo5, Giuseppe Viale2, Marco Colleoni5. 1. Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: emilia.montagna@ieo.it. 2. Department of Pathology, European Institute of Oncology, Milan, Italy. 3. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. 4. Division of Endoscopy, European Institute of Oncology, Milan, Italy. 5. Division of Medical Senology, European Institute of Oncology, Milan, Italy.
Abstract
INTRODUCTION: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. PATIENTS AND METHODS: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). RESULTS: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). CONCLUSION: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.
INTRODUCTION: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. PATIENTS AND METHODS: The present study focused on the treatment and outcomes of breast cancerpatients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). RESULTS: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). CONCLUSION:Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.
Authors: Medha Suman; Pierre-Antoine Dugué; Ee Ming Wong; JiHoon Eric Joo; John L Hopper; Tu Nguyen-Dumont; Graham G Giles; Roger L Milne; Catriona McLean; Melissa C Southey Journal: Clin Epigenetics Date: 2021-01-18 Impact factor: 6.551
Authors: Joanne Aisha Mosiun; Muhammad Syafiq Bin Idris; Li Ying Teoh; Mei Sze Teh; Patricia Ann Chandran; Mee Hoong See Journal: Int J Surg Case Rep Date: 2019-10-07